EMA Application withdrawn: Puldysa (idebenone;titanium dioxide) — Santhera Pharmaceuticals (Deutschland) GmbH

View source ↗

Summary

EMA withdrawn the application for Puldysa (idebenone; titanium dioxide) by Santhera for Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Puldysa (idebenone)

Snippet

Status: Application withdrawn. Therapeutic area: Muscular Dystrophy, Duchenne. MAH: Santhera Pharmaceuticals (Deutschland) GmbH. Orphan medicine